- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: Thyroid follicular cell.
Displaying page 1 of 2.
| EudraCT Number: 2017-003668-11 | Sponsor Protocol Number: E7080-G000-604 | Start Date*: 2018-07-30 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Eisai Ltd. | ||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: solid tumors or lymphomas, as defined in parent protocol | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-001032-12 | Sponsor Protocol Number: PANTHERA | Start Date*: 2008-10-28 | |||||||||||||||||||||
| Sponsor Name:Universitätsklinikum Schleswig-Holstein | |||||||||||||||||||||||
| Full Title: Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer | |||||||||||||||||||||||
| Medical condition: recurrent/advanced follicular, papillary or anaplastic thyroid cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Prohibited by CA) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2011-000144-21 | Sponsor Protocol Number: UCL/10/0299 | Start Date*: 2011-10-05 | |||||||||||||||||||||
| Sponsor Name:University College London | |||||||||||||||||||||||
| Full Title: ION– Is ablative radiOiodine Necessary for low risk differentiated thyroid cancer patients | |||||||||||||||||||||||
| Medical condition: Patients with differentiated thyroid cancer who are classed as low risk | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2018-001066-42 | Sponsor Protocol Number: GETNE-T1812 | Start Date*: 2020-02-20 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Spanish Group of Neuroendocrine Tumors (GETNE) | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC). Advanced medullary thyroid carcino... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-002269-47 | Sponsor Protocol Number: STH18441 | Start Date*: 2015-12-02 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||||||||||||||||||||||||||||||||||||||
| Full Title: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Iodine-refractory thyroid cancer of papillary, follicular, Hürthle cell or poorly differentiated carcinoma | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2022-002419-48 | Sponsor Protocol Number: GETNE-T2216 | Start Date*: 2023-03-27 | |||||||||||||||||||||
| Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) | |||||||||||||||||||||||
| Full Title: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. | |||||||||||||||||||||||
| Medical condition: Patients with radioiodine-refractory differentiated thyroid cancer (DTC). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2007-005933-12 | Sponsor Protocol Number: E7080-G000-201 | Start Date*: 2009-10-29 | |||||||||||
| Sponsor Name:Eisai Limited | |||||||||||||
| Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified... | |||||||||||||
| Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005017-71 | Sponsor Protocol Number: CHOCOLATE | Start Date*: 2016-04-02 | |||||||||||
| Sponsor Name:Centre François Baclesse | |||||||||||||
| Full Title: Diagnostic value of 18F-choline PET in patients with indeterminate cytology thyroid nodule : A pilot study | |||||||||||||
| Medical condition: Patient with a thyroid nodule ≥15mm with indefinite cytology according to the 2008 Bethesda classification (vesicular lesion of undetermined significance; follicular neoplasm or cell Hürthle; lesi... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-012007-25 | Sponsor Protocol Number: BAY43-9006/14295 | Start Date*: 2009-10-21 | |||||||||||||||||||||
| Sponsor Name:Bayer AG | |||||||||||||||||||||||
| Full Title: A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | |||||||||||||||||||||||
| Medical condition: Differentiated thyroid cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) NL (Completed) FR (Completed) DK (Completed) SE (Completed) BE (Completed) AT (Completed) SK (Completed) BG (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2014-005199-27 | Sponsor Protocol Number: E7080-G000-211 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Eisai Ltd. | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily W... | |||||||||||||
| Medical condition: 131I-refractory differentiated thyroid cancer (DTC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-000423-14 | Sponsor Protocol Number: D1532C00065 | Start Date*: 2013-05-23 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Diff... | ||
| Medical condition: Differentiated Thyroid Cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) DE (Completed) IT (Completed) FR (Completed) DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-006615-80 | Sponsor Protocol Number: matisse1 | Start Date*: 2007-02-23 |
| Sponsor Name:Royal Marsden Nhs Foundation Trust | ||
| Full Title: A Pilot Study in Metastatic Advanced Thyroid Cancer Evaluating the Safety and Efficacy of Sorafenib | ||
| Medical condition: Patients with localled advanced or metastatic thyroid cancer . histological sub-types will include differentiated and medullary thyroid cancer. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2022-000339-21 | Sponsor Protocol Number: JK08.1.01 | Start Date*: 2022-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Salubris Biotherapeutics, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Unresectable Locally Advanced or Metastatic Cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-002968-27 | Sponsor Protocol Number: INTERMEDIATE-01 | Start Date*: 2020-02-18 | |||||||||||
| Sponsor Name:Centre François Baclesse | |||||||||||||
| Full Title: Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration (3.7 GBq I131 after rhTSH) versus decision o... | |||||||||||||
| Medical condition: Differentiated thyroid cancer - subgroup of patients with intermediate risk of postoperative residual disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-023783-41 | Sponsor Protocol Number: E7080-G000-303 | Start Date*: 2011-07-05 | |||||||||||
| Sponsor Name:Eisai Limited | |||||||||||||
| Full Title: A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I- Refractory Differentiated Thyroid Cancer | |||||||||||||
| Medical condition: 131I-refractory differentiated thyroid cancer (DTC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed) DE (Completed) ES (Completed) PL (Completed) DK (Completed) AT (Completed) IT (Completed) SE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-001771-21 | Sponsor Protocol Number: XL184–311 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Exelixis, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-... | |||||||||||||
| Medical condition: Radioiodine-Refractory Differentiated Thyroid Cancer which has progressed after prior VEGFR-targeted therapy | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) FR (Completed) AT (Prematurely Ended) HU (Completed) ES (Ongoing) PL (Trial now transitioned) CZ (Completed) HR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002260-14 | Sponsor Protocol Number: UC-0105/1612 | Start Date*: 2017-04-03 |
| Sponsor Name:UNICANCER | ||
| Full Title: Secured access to pembrolizumab for adult patients with selected rare cancer types. | ||
| Medical condition: Patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, primary central nervous system lymphomas (PCNSL), rare t... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003712-27 | Sponsor Protocol Number: P1605-SUR-D23 | Start Date*: 2022-07-27 | |||||||||||
| Sponsor Name:IMV Inc. | |||||||||||||
| Full Title: A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, with and without Intermittent LowDose Cyclophospha... | |||||||||||||
| Medical condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) FR (Completed) PL (Completed) HU (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-002576-18 | Sponsor Protocol Number: A4061027 | Start Date*: 2006-11-24 | |||||||||||
| Sponsor Name:Pfizer Ltd. | |||||||||||||
| Full Title: A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT | |||||||||||||
| Medical condition: Treatment of patients with 131I-refractory metastatic or unresectable locally-advanced papillary, follicular, or Hurthle-cell thyroid cancer who are also refractory to, or intolerant of, or have cl... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-000461-23 | Sponsor Protocol Number: CA209-627 | Start Date*: 2017-03-07 | ||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
| Full Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies | ||||||||||||||||||
| Medical condition: Advanced/Metastatic malignancies | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
